Detalles de la búsqueda
1.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38634928
2.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet
; 399(10336): 1695-1707, 2022 04 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405085
3.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37248424
4.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676282
5.
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders.
Oncologist
; 25(6): e946-e954, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32181960
6.
Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort.
World J Urol
; 38(7): 1757-1764, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31605196
7.
Chemotherapy for Muscle-Invasive Bladder Cancer.
Curr Treat Options Oncol
; 17(1): 6, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26810055
8.
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Oncology
; 88(5): 273-80, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25592399
9.
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors.
Cancers (Basel)
; 16(8)2024 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38672547
10.
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.
Clin Exp Metastasis
; 2024 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38850317
11.
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Target Oncol
; 2024 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38704759
12.
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma.
Eur Urol Focus
; 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38839505
13.
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study.
Clin Genitourin Cancer
; 22(3): 102074, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38616147
14.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Eur Urol Oncol
; 7(1): 102-111, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37481365
15.
Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma.
Cancer Drug Resist
; 6(3): 517-546, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37842234
16.
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
J Immunother Cancer
; 11(1)2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36627145
17.
Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort.
Cancers (Basel)
; 15(19)2023 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37835503
18.
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
Clin Exp Med
; 23(8): 5413-5422, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37917218
19.
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).
Tumori
; 109(3): 324-334, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35674125
20.
Corrigendum: Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals.
Front Cardiovasc Med
; 10: 1309921, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37953759